Analysts say the patent fight pitting Bristol-Myers Squibb and Sanofi-Aventis against generics maker Apotex could affect Eli Lilly's pipeline drug prasugrel if Apotex is allowed to continue selling the generic form of Plavix. Analysts say that if research fails to show there is significant difference between the new Lilly product and the generic Plavix, sales of prasugrel could be hit. A Lilly executive says the company is testing Plavix and prasugrel head-to-head because it anticipates competition against a generic.

Related Summaries